Curriculum Vitae, Ira David Glick, M.D. Ira David Glick, M.D. Pacific Research Partners, LLC 901 Clay Street Oakland, CA 94607

Transcription

1 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) Fax (208) AFFILIATIONS: Collaborative Neuroscience Network, LLC Valley View Street, Suite 3 Garden Grove, CA Collaborative Neuroscience Network, LLC 2600 Redondo Avenue, Suites 415 & 500 Long Beach, CA Collaborative Neuroscience Network, LLC S. Vermont Avenue, Suite F-100 Torrance, CA Stanford University Medical Hospital EDUCATION: Ira David Glick, M.D. Pacific Research Partners, LLC 901 Clay Street Oakland, CA B.S., Dickinson College, Carlisle, Pennsylvania 1961 M.D., New York Medical College INTERNSHIPS AND RESIDENCIES: Candidate, New York Psychoanalytic Institute, New York, NY Chief Resident (Psychiatry), Hillside Hospital Second Year Resident (Psychiatry), Mt. Zion Hospital, San Francisco, CA First Year Resident (Psychiatry), Hillside Hospital, Glen Oaks, New York Rotating Internship, Beth Israel Hospital, New York, NY Updated 12/21/2018 1

2 LICENSURE: Maryland Medical License (License number available on request) 1980 Mental Health Administrator, Commission on Certification in Administrative Psychiatry of the American Psychiatric Association 1968 Diplomate of the American Board of Psychiatry and Neurology 1963 California State Medical License - (G 9084) 1963 Diplomate of the National Board of Medical Examiners New York State Medical License PROFESSIONAL EXPERIENCE: Principal Investigator, Present Pacific Research Partners, LLC, Oakland, CA Professor Emeritus, Psychiatry, June 2010 Present Director, Schizophrenia Research Clinic, 1993 June 2010 Director of Inpatient & Partial Hospitalization Services, Stanford University School of Medicine & Stanford University Hospital Acting Deputy Chief of Staff and Chief of Psychiatry, Veterans Administration Hospital, Palo Alto, CA Associate Medical Director, Payne Whitney Clinic, Department of Psychiatry, The New York Hospital Senior Science Advisor to the Director, National Institute of Mental Health, Rockville, MD Director, Inpatient Services, Director, of the Family Therapy Program, Director, Outpatient Department, Cornell Medical Center Chief, Clinical Research Ward, (Renamed the Inpatient Treatment & Research Service, 5/1/75) Director, Medical Student Education, Langley Porter Neuropsychiatric Institute and Dept. of Psychiatry, School of Medicine University of California, San Francisco Service Record: Captain, Army of the United States, Chief, Psychiatry Service, U.S. Army Hospital Specialized Treatment Center, Fort Gordon, Georgia Staff Psychiatrist and Research Associate, Hillside Hospital, Glen Oaks, New York Updated 12/21/2018 2

3 INVESTIGATOR EXPERIENCE: Phase I Addiction Adolescent Psychiatry Binge Eating Disorder Bipolar Disorder Depression Diabetes Fibromyalgia Migraine Schizophrenia and Schizoaffective Disorder Sexual Disorder Smoking Cessation Tardive Dyskinesia INTEREST: ADHD Alzheimer s Disease Anxiety Dementia Multiple Sclerosis Post Traumatic Stress Disorder (PTSD) Sleep Disorders CLINICAL TRIAL EXPERIENCE: Phase I A Phase Ib, Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 ml) in Patients with Schizophrenia or Schizoaffective Disorder A Phase I, Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing XXX Extended-Release IM 156 mg/1 ml (100 mg eq) with XXX in Subjects with Schizophrenia or Schizoaffective Disorder A Phase I, XXX Sub-study 002: Study of XXX and Android App Performance and Usability. A Phase I, RW2 Confirmatory Study of the XXX system. The system is designed to enable mental health patients to measure and monitor their medication adherence as well as other information such as mood, rest, and activity. A Phase I Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156 mg/1.0 ml) Versus XXX Extended-Release Injectable Suspension (156 mg/1.0 ml) in Schizophrenia Patients Already Stabilized on XXX A Phase I, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX Following Administration to the Deltoid or Gluteal Muscle in Adults with Schizophrenia or Schizoaffective Disorder A Phase I, Reliability and validity of an online neurocognitive test battery, the XXX Test, in normal healthy adults A Phase I Study of XXX and XXX Co-administered with XXX in Adults with Schizophrenia Updated 12/21/2018 3

4 CLINICAL TRIAL EXPERIENCE (continued): Phase II-IV Addiction A Phase III, Open-Label, Depot XXX Treatment Extension Study in Subjects With Opioid Use Disorder A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder A Phase III, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Doseoptimization Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adults Aged Years with Moderate to Severe Binge Eating Disorder Bipolar Disorders A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder A Multicenter, Randomized, Double-blind Trial of XXX versus Placebo for the Acute Treatment of Subjects Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder A Phase III, Randomized, Double-Blind,Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Fixeddose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of XXX in Patients with Bipolar I Depression A Phase III, 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects Updated 12/21/2018 4

5 CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX Tablet for Sublingual Administration XXX in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects Who Are on Lithium or Valproate A Phase IIIb, Double-Blind, Placebo-Controlled Trial of XXX in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder Depression A Double-Blind, Placebo-Controlled, Phase II Trial to Test Efficacy and Safety of XXX as Adjunct to Current Antidepressant Therapy in Patients with Major Depressive Disorder (MDD) with an Inadequate Response to Current Antidepressants A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder A Double-Blind, Placebo-Controlled, Fixed-Dose Study of XXX in Patients with Major Depressive Disorder A Study of XXX Plus XXX in Treatment-Resistant Depression (TRD) A Phase II/III, Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of XXX Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive XXX in Major Depressive Disorder An Open-Label, Single-Arm, Multicenter, Prospective, Phase IV, Interventional, Flexible Dose Study to Evaluate the Effectiveness of XXX on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder - Goal Achievement After a Change to XXX in Adults With Major Depressive Disorder An Phase III, Open-label, Long-term Safety Study of XXX as Adjunctive Therapy in Patients with Major Depressive Disorder A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in Major Depressive Disorder Updated 12/21/2018 5

6 CLINICAL TRIAL EXPERIENCE (continued): A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of XXX in the Treatment of Subjects with Severe Depression despite Antidepressant Treatment A Phase III, Open-label Long-term Extension Safety Study of Intranasal XXX in Treatmentresistant Depression A Phase III, 8-Week Prospective Randomized, Controlled, Single-Blind Trial of the XXX vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults with Major Depressive Disorder A Phase III, Non-Interventional Study of Subjects who have participated in XXX, A Study of Adjunctive Treatment of Major Depressive Disorder A Phase II, Multicenter Double-Blind Placebo-Controlled Dose Finding Study of XXX in Patients with Major Depressive Disorder (MDD) A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXX as an adjunctive therapy in patients with major depressive disorder with an inadequate response to antidepressant treatment A Phase III Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy A Phase IIIb, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction of XXX as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy A Phase II, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of XXX in Subjects with Major Depressive Disorder An Interventional, open-label, flexible dose, exploratory study of XXX as adjunctive treatment of irritability in patients with major depressive disorder and an inadequate response to antidepressant therapy A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy Updated 12/21/2018 6

7 CLINICAL TRIAL EXPERIENCE (continued): A Phase III, Open-Label Extension Study to Assess the Safety and Tolerability of Treatment With XXX in Patients Who Have Completed Study XXX A Phase II, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of XXX in the Adjunctive Treatment of Subjects with Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment A Phase III Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX in Major Depressive Disorder A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of XXX on Cognitive Dysfunction in Adult Subjects with Major Depressive Disorder A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of XXX as Monotherapy Treatment in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of XXX Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment A Phase III,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of XXX in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant Updated 12/21/2018 7

8 CLINICAL TRIAL EXPERIENCE (continued): A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallelgroup, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD) A Phase III,, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Major Depressive Disorder A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX Treatment A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long- Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy Fibromyalgia An Open-label Extension Study of XXX for 52 weeks in Pain Associated with Fibromyalgia A randomized, double-blind, double-dummy, placebo- and active-controlled, multi-center study of XXX in subjects with pain associated with fibromyalgia Migraine A Phase III, Multicenter, Randomized, Open-label Study to Evaluate the Longterm Safety and Tolerability of Oral XXX for the Prevention of Migraine in Patients with Episodic Migraine A Phase III, Randomized, Double blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention Updated 12/21/2018 8

9 CLINICAL TRIAL EXPERIENCE (continued): A Multicenter, Open Label, Long-Term Safety Study of XXX in Patients with Acute Migraines A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy, Tolerability, and Safety Study of XXX in Episodic Migraine with or Without Aura A Phase III, Open-label, LonG-term, Safety Study of XXX (100 mg and 200 mg) in the Acute Treatment Of MigRaine A Phase III, Study of Three Doses of XXX (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of LY in Patients with Episodic Migraine the XXX 2 Study A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Administered Intravenously in Patients with Chronic Migraine Post-Traumatic Stress Disorder A 40-Week Open-Label Extension Study to Evaluate XXX SL Taken Daily at Bedtime in Patients with PTSD A Phase III, 12-Week Open-Label Extension Study to Evaluate XXX Taken Daily at Bedtime in Patients with PTSD A Phase III, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Taken Daily at Bedtime in Patients with Military-Related PTSD Schizophrenia and Schizoaffective Disorder A Phase II Randomized, Sham-Controlled Study of XXX as an adjunct to standard-of-care treatment for schizophrenia Tocreate opportunities for the XXX Sponsor to interface with people with schizophrenia and to obtain their feedback on XXX prototypes A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication Updated 12/21/2018 9

10 CLINICAL TRIAL EXPERIENCE (continued): A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia A Double-blind, Randomized, Active-controlled, Parallel-group Study of XXX 6-Month Formulation A Phase III, Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder A Phase IIb/III, Adaptive, Multi-center, Prospective, Randomized, Double-blind, Placebocontrolled Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults Pilot study for Validation Test Plan XXX study A Phase III, Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of XXX in Patients with Schizophrenia A Phase IIb, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics A Phase III, 52-Week, Open-Label, Extension Study of XXX for the Adjunctive Treatment of Schizophrenia A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Treatment for the Negative Symptoms of Schizophrenia A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive XXX for the Treatment of Schizophrenia A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label Flexible-Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia who Have Been Incarcerated A Phase III Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia A Phase III, One Year, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as a Maintenance Treatment in Patients with Schizophrenia XXX for Cannabis Use Disorder in Schizophrenia Updated 12/21/

11 CLINICAL TRIAL EXPERIENCE (continued): A Phase III, Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia A Phase II, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy, safety and tolerability of XXX for the treatment of negative symptoms of schizophrenia An Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects With Schizophrenia A Phase II, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerability of XXX in Subjects with Schizophrenia with Alcohol Use A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of XXX (90-mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks An Exploratory, Multicenter, Open-label, Flexible-dose XXX Trial in the Treatment of Adults with Early-Episode Schizophrenia A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia A Phase II, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Schizophrenia to Mitigate or Prevent XXX -Induced Weight Gain A Phase III, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of XXX in Subjects with Acute Exacerbation of Schizophrenia A Phase II, partial-blind, multi-center extension study to evaluate the long-term safety and health outcomes of XXX in subjects who completed Study XXX (Long-Term Safety and Efficacy of XXX in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study XXX) A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia Updated 12/21/

12 CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-blind, Placebo-controlled, Parallel, 12 Week, Phase III Study of 2 Doses of XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy A Phase III Multicenter 40-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy A Phase IIb, 12 week randomized, double-blind, placebo-controlled, parallel group, multiple dose, proof-of-concept study to evaluate the effects of XXX on cognition in stable schizophrenia patients A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Non-smokers A Phase III, Randomized, Multicenter, Double-Blind, Non-inferiority Study of XXX 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of XXX on Schizophrenia Negative Symptoms A Multicenter, Open-label, Single-arm Flexible Dose (20-80 mg Twice Daily, Phase III Study of XXX in Outpatients who complete (rollover) a previous XXX Study and a Study duration of up to 2 years after US XXX Monotherapy Launch A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Addon XXX on Schizophrenia Negative Symptoms A Phase III, Short-term, Multicenter, Placebo-controlled, Randomized Withdrawal Study of XXX Monohydrate with DSM-IV-TR Schizophrenia A Phase III, Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with XXX Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia Updated 12/21/

13 CLINICAL TRIAL EXPERIENCE (continued): A Multicenter, Double-Blind Comparison of XXX and Aripiprazole in Patients with DSM-IV- TR Schizophrenia Followed by Open-Label Treatment with XXX A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder Tardive Dyskinesia A Phase III, Open-Label Rollover Study for Continuing XXX Administration for the Treatment of Tardive Dyskinesia A Phase III, Open-Label, Safety and Tolerability Study of XXX for the Treatment of Tardive Dyskinesia A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel, Fixed-dose Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Tardive Dyskinesia A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered XXX in Subjects with Drug- Induced Tardive Dyskinesia Other Indications A Phase III, Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of XXX in Type 1 Diabetes Mellitus Patients Updated 12/21/

14 CLINICAL TRIAL EXPERIENCE (continued): A Phase II/III Randomized, Double-blind, Placebo-controlled trial of XXX in Subjects with Obsessive Compulsive Disorder A Randomized Withdrawal, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of XXX Tablet, XXX, in Patients with Moderate-to-Severe Chronic Low Back Pain A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered XXX in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal) Updated 12/21/

15 FUNDED RESEARCH ACTIVITIES: 2009 Educational Outreach Initiative Grant 2008 XXX, A Multi-center, Double-Blind, Randomized, Active-Controlled, Study to Evaluate the Long-term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia 2008 Schizophrenia Trials Network associated with NIMH Contract XXX Comparison of Optimal Antipsychotic Treatment for Schizophrenia (COATS: A Pilot Study) XXX in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS: A Pilot Study) 2008 Keeping Up With Advances in Psychopharmacology in the New Millenium, four lectures at medical schools in Israel, supported by the Sarlo Fund and the Ingrid D. Tauber Philanthropic Fund from the Jewish Community Endowment Fund, San Francisco, June, XXX, Validation of the Reasons for Antipsychotic Discontinuation/Continuation Questionnaire (RAD-Q) and Interview (RAD-I) 2007 A Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral XXX in Adolescents with Schizophrenia XXX, A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect Of XXX Versus XXX In Patients With Schizophrenia Using the XXX 2007 American College of Neuropsychopharmacology, ACNP Public Outreach Initiative Schizophrenia Education Day. (also supported by XXX ) 2006 XXX, An Open-Label Study of Equetro in Outpatients with Aggressive Symptoms & Behavior (investigator initiated study) 2006 XXX, A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 16-week Study of XXX Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to XXX Monotherapy XXX, A Multi-center, Double-Blind, Flexible-Dose, 6-month Trial Comparing the Efficacy and Safety of XXX in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia. Updated 12/21/

16 FUNDED RESEARCH ACTIVITIES (continued): 2006 CAMP (Foundation for NIH), Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to XXX vs. XXX 2005 American College of Neuropsychopharmacology, ACNP Public Outreach Program 2005 XXX vs. XXX Double Blind. (investigator-initiated Study) 2005 XXX, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of XXX in the Treatment of Schizophrenia Co-Investigator of a XXX Grant for a project Fostering Collaboration Through Clinical Education: A Clinical Neurosciences Seminar, Clinic and Curriculum Series in Child Psychiatry and Pediatric Neurology (with Joshi SV, Chang KD and Hahn J) XXX Education Fund 2004 XXX, Comparison of Atypicals for First Episode (CAFE) 2004 XXX, The Treatment of Schizophrenia and OCD Symptomatology with XXX (investigator-initiated study) Pfizer, Zodiac International Schizophrenia Study to Compare the Cardiovascular Safety of XXX and XXX XXX, A 12 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Evaluation of XXX as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patient with Schizophrenia or Schizoaffective Disorder 2003 XXX, Efficacy and Weight Reduction Effects of XXX in Stabilized Patients with Schizophrenia and Weight Associated with Atypical Antipsychotics (investigator-initiated study with Reaven) XXX, An Open-Label Follow-Up Study of the Long-Term Safety of XXX in Patients with Psychosis XXX, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Flexible Doses of XXX Versus XXX In the Treatment of Patients with Treatment-Resistant Schizophrenia 2000 National Institute of Mental Health, sub-contract, Comparative Effeciveness of Antipsychotic Medications in Patients with Schizophrenia CATIE: Human Genetics Initiative Updated 12/21/

17 FUNDED RESEARCH ACTIVITIES (continued): 1999 XXX, XXX vs. Placebo in the Treatment of Subjects with Schizophrenia or Schizoaffective Disorder 1999 Development of a Model Psychopharmacology Curriculum for Psychiatric Residents. (through the American Society of Clinical Psychopharmacology) Supported in part by XXX 1998 XXX Corporation, A Prospective, Randomized, International, Parallel-group Comparison of XXX vs. XXX in the Reduction of Suicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are at Risk for Suicide 1998 Research Grant for the investigator-initiated study, XXX vs XXX for the Long-Term Treatment of Schizophrenia and Schizoaffective Disorder with Marder S XXX, The Acute and Long-Term Efficacy of XXX in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with XXX 1998 XXX Pharmaceuticals, A Multi-Center, Placebo Controlled Double Blind Study Comparing the Safety and Efficacy of XXX with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care 1997 XXX Research Grant for the study, A Multi-center, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients 1997 XXX Research Grant for the study, A Phase III Double-Blind Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control 1996 XXX Research Grant for the study, A Multi-center, Open, Randomized Comparison of and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder 1995 XXX Unrestricted grant to develop a Model Psychopharmacology Curriculum for Residents (Committee Chair) under the auspices of the American Society of Clinical Psychopharmacology 1995 XXX Research Grant for the study, XXX versus XXX in the Treatment of Schizophrenia and other Psychotic Disorders 1995 XXX Grant for the study, Dose-Response Study in the Treatment of Negative Symptoms of Schizophrenia with XXX Updated 12/21/

18 FUNDED RESEARCH ACTIVITIES (continued): 1995 XXX Research Grant for the study, A Comparative Cost Effectiveness Study of XXX and Usual Care versus XXX and Usual Care in the Treatment of Bipolar Disorder 1993 (Stanford) A Double-Blind, Haldol-Referenced, Placebo-Controlled Study 1993 Pharmacologic Medication Discovery & Development Project (PMDDP) Supported by XXX 1993 XXX for the Study, Treatment of Adolescent Depression with XXX 1993 XXX Grant for the study, Safety and Efficacy of XXX in the Prevention of Mania in Patients with Bipolar Disorder National Institute of Mental Health Grant, Marital Treatment for Bipolar Disorder Patients, Co-Principal Investigator with John Clarkin, PhD, P.I. $520, (Cornell) XXX Research Grant for the study: XXX in the & Prevention of Mania 1992 XXX Research Grant for the study: XXX for the Treatment of Schizophrenia and Schizoaffective Disorder 1992 (Cornell) XXX Research Grant for the study: The Safety and Efficacy of XXX in Schizophrenic Patients 1991 XXX Grant for the study, XXX in the Treatment of the Negative Symptoms of Schizophrenia 1987 XXX Research Award for the project, Delivery and Compliance to Good Medical Treatment National Institute of Mental Health Grant for project Inpatient Family Intervention: Evaluation of Practice $180, National Institute of Mental Health, Cooperative Clinical Agreement Award for the project, Treatment Strategies in Schizophrenia, National Institute of Mental Health - Biomedical Research Support Grant for the study Inpatient Family Intervention: A Controlled Study National Institute of Mental Health Contract -to develop a Model Psychopharmacology Curriculum for Psychiatric Residency Training (with David Janowsky MD) under the auspices of the American College of Neuropsychopharmacology $ 4,290 Updated 12/21/

19 FUNDED RESEARCH ACTIVITIES (continued): Endo Research Grant for the study XXX vs. XXX: Double Blind Investigation of the Treatment of Acute Schizophrenia National Institute of Mental Health Grant for Medical Student Psychiatric Education, Vice Chancellor's Advisory Committee on Instructional Improvements Grant, UCSF, for project Effectiveness and Efficiency in Small Group Teaching with Mary Malloy, MD Lederle Research Grant for the study XXX Treatment in Schizophrenia National Institute of Mental Health Grant for the project XXXShort vs. Long Psychiatric Hospitalization: A Controlled Study G.D. Searle Research Grant for the study: Pseudopregnancy Treatment of Periodic Psychiatric Illness EDITORIAL AND ADVISORY BOARDS: Advisory Board, Pfizer. Anxiety Disorders Editorial Board, The Physician and Sports Medicine Editorial Board, The Journal of Clinical Psychiatry 2002, 03,04,05 Advisory Board, Bristol-Myers Squibb California Neuroscience 2002, 04,05 Advisory Board, Shire Pharmaceuticals Board of Directors, National Foundation for Depressive Illness, Inc 2001, 2005 Advisory Board, Pfizer (Geodon) Pharmaceuticals Advisory Board, NPSP Pharmaceuticals Bipolar Clinical Advisory Board, Boca Raton Advisory Board, Hoechst Marion Roussel (Aventis) Advisory Board, Otsuka Pharmaceuticals Advisory Board, Zeneca Pharmaceuticals Advisory Board, Janssen Pharmaceutica and Research Foundation Advisory Board, Institute for Healthcare Quality, Minneapolis CNS Science Advisory Board, Wyeth Ayerst Pharmaceutical Gralnick Foundation Awards Committee Board Member, The National Mental Health Project Sertindole Advisory Board,, Neuroscience Venture, Abbott Laboratories Advisory Board, MultiMedia Reviews in Psychiatry, Massachusetts General Hospital Progress in Neuropsychology and Biological Psychiatry National Council of Advisors on Development and External Affairs, UCSF Updated 12/21/

20 EDITORIAL AND ADVISORY BOARDS (continued): The Journal of Family Psychotherapy Board of Advisors, Dickinson College The Journal of Family Therapy (England) Journal of Clinical Psychopharmacology Contemporary Family Therapy - An International Journal Family Process AWARDS: 2010 National Alliance on Mental Illness (NAMI) exemplary Psychiatrist Awards 2008 The American College of Psychiatrists (ACP) Distinguished Service in Psychiatry Award, one award given each year to recognize distinguished achievements and leadership in the field of psychiatry The Association for Academic Psychiatry, Distinguished Life Fellow, given each year for mastery in a career dedicated to educational endeavors, demonstrated generativity (this one either I think we need to check it) by unselfishly guiding the next generation of academic psychiatrists, and engaged in passing on the traditions of the past to the next generation of academic psychiatrists 2006 Dickinson College Distinguished Alumni Award for Professional Achievement. This yearly award names alumni who have demonstrated outstanding accomplishment, as well as strength of character, in their professional and civic lives CINP 2006 Lundbeck Neuroscience Foundation Prize for Education in Psychiatry and Neurology, one award given every 2 years for education in psychiatry and neuroscience to an individual (or group) who has attained particularly valuable achievements in the field of postgraduate education in psychiatry and neuroscience First Annual Irma Bland Award for Excellence in Teaching Residents, given annually by the American Psychiatric Association to Departments of Psychiatry for outstanding and sustaining contributions made as a faculty Paul Hoch Distinguished Service Award for Contributions to the College, presented by the American College of Neuropsychopharmacology 2004 Excellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. In recognition of contributions to the educational mission of the school Nominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM 2003 Metzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA Updated 12/21/

21 AWARDS (continued): 2003 Fulbright Lecturing Award, India 2002 Rockefeller Foundation Award for Residence at Bellagio, Italy, Summer Distinguished Contribution to Family Systems Research Award. This annual AFTA award recognizes an individual for outstanding research on subjects central to the field of family therapy Annual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) of the APA, recognizes a member of NCPS who has made significant and exceptional contributions to the field of psychiatry. PUBLICATIONS: Books, Monographs, Bibliographies: (More available upon request) 1. Glick ID, Balon R (eds.): The American Society of Clinical Psychopharmacology Model Psychopharmacology Curriculum for Medical Students, ASCP, POB 40395, Glen Oaks, NY 11004, Keitner G, Heru A, Glick I: Clinical Manual of Couples & Family Therapy. American Psychiatric Publishing, Inc., Arlington, VA, 322 pgs, Tandon R, Glick ID, Goldman M, Jibson MD, Marder SR, Mellman TA: Managing Schizophrenia, A Comprehensive Primer McMahon Publishing Group, New York, Ritvo EC, Glick ID: The Concise Guide to Marriage and Family Therapy. American Psychiatric Press, Inc. Washington, DC, 2002, pp Spanish Edition translated by Jose Luis Nunez Herrejon, Madrid, Manual Moderno pubs. 5. The ASCP Model Psychopharmacology Curriculum, for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology. The American Society of Clinical Psychopharmacology, Inc., P.O. Box 40395, Glen Oaks, NY Glick ID (Editor of all four editions with a large committee for each edition) : 1999 First Edition Second Edition Third Edition Fourth Edition 2008 Fifth Edition Updated 12/21/

22 PUBLICATIONS (continued): Invited Lectures: 1) Schizophrenia (with M. Jibson), 2) Combining Pharmacotherapy & Psychotherapy, 3) The Art of Psychopharmacology (with R. Balon) 6. DeBattista C, Glick ID (ed.). The Medical Management of Depression. Essential Medical Information Systems, Inc. Durant, OK: Second Edition 2002 Third Edition 7. Glick ID (ed): Treating Depression, San Francisco, Jossey-Bass, Translated into Turkish by Yayin Dagitrin, Global Publishers. 8. Clarkin JF, Haas GL, Glick ID (eds): Affective Disorders and the Family: Assessment and Treatment, New York, Guilford Press, Grunebaum H, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: (Formulated by the Committee on the Family, Group for the Advancement of Psychiatry), The Family, the Patient, and the Psychiatric Hospital: Toward a New Model. New York, Brunner/Mazel, l Glick ID, Janowsky DS, Salzman C, Shader RI: A Model Psychopharmacology Curriculum for Psychiatric Residents. Nashville, TN, The American College of Neuropsychopharmacology, 1984 a) Translated into Japanese, Japanese Journal of Psychopharmacology, 6: , 1986 b) Reprinted in Psychopharmacology: The Third Generation of Progress, edited by Herbert Y. Meltzer. Raven Press, New York, , 1987 c) Translated into Japanese for the Lectures on Clinical Psychiatric Issues, Part II, edited by Yamaguchi T, Tajima S. Chugoku-shikoku Psychotherapy Workshops, Hiroshima and Nichidai Seishin-shinkeika Workshops, Tokyo Glick ID, Hargreaves WA: Psychiatric Hospital Treatment for the 1980s: A Controlled Study of Short Versus Long Hospitalization. Lexington, Mass., Lexington Press, Glick ID, Kessler DR: Marital and Family Therapy. New York, Grune and Stratton, Summarized in Foote C, Levy RJ, Sander FEA, Cases and materials on family law, second edition, Boston, Little, Brown, 1976, pp Second Edition Translated into Japanese by Koji Suzuki, MD; 2nd printing, Translated into Chinese by Xiang De-Zhao, MD Third Edition, with Clarkin JF & Kessler DR. Published by American Psychiatric Press, Inc., Washington, D.C Fourth Edition, with Berman E, Clarkin JF & Rait D. American Psychiatric Press, Inc., Washington, D.C Spanish Edition, translated by Raquel Martin Lanas, Madrid, Grupo Medica Updated 12/21/

23 PUBLICATIONS (continued): 13. Glick ID, Haley J: Family Therapy and Research: An Annotated Bibliography of Articles and Books Published New York, Grune and Stratton, Glick ID, Weber D, Rubinstein D, Patten J: Family Therapy and Research: An Annotated Bibliography of Articles, Books, Videotapes and Films Published , 2nd Edition, New York, Grune and Stratton, Haley J, Glick ID: Psychiatry and the Family, An Annotated Bibliography of Articles Published, Palo Alto, California, Family Process, (Extended CV available upon request) Updated 12/21/